Notable efficacy for an off-the-shelf immunotherapy[1][2]
TECVAYLI (teclistamab) demonstrated notable efficacy for an off-the-shelf immunotherapy, with 59.4% of patients achieving VGPR or better[1]
- After 23 months of follow-up, ORR was 63%[1]
- 45.5% patients achieved ≥CR [1]
- 81.5% of MRD evaluable patients achieve MRD negativity at any point[1]
- The median time to first response was 1.2 months (range: 0.2–5.5), and the median time to achieved ≥CR was 4.6 months (range: 1.6-18.5)[1]
Overall response rate[1]
ORR across patient populations[4][3]
Efficacy was consistent regardless of cytogenetic risk or extent of prior therapy refractoriness[4][3]
Adapted from Moreau et al. 2022[3]
*del(17p), t(4;14) and/or t(14;16)[3]
**≥1 PI, ≥1 IMiD and ≥1 anti-CD38 mAb[3]
†≥2 PI, ≥2 IMiD and ≥1 anti-CD38 mAb[3]
^Median follow up of 14.1 months
Progression-free survival[1]
Median FU:23 months
Duration of response[1]
Median FU:23 months
Overall survival[1]
Median FU:23 months
For further information regarding TECVAYLI including full indications, all adverse effects and data please refer to the Israeli MOH prescribing information: https://israeldrugs.health.gov.il/#!/byDrug
The data in this presentation is based on published clinical studies, please see references at the bottom of the slides/throughout the presentation.
CP-412257 - November 2023
